Download PDF
Der Nuklearmediziner 2011; 34(02): 99-107
DOI: 10.1055/s-0031-1280787
Hybridbildgebung und Strahlentherapie – aktuelle Entwicklungen
Georg Thieme Verlag KG Stuttgart · New York

Welche neuen PET-Tracer braucht die Strahlentherapie?

Novel Tracer for Radiation Treatment Planning
S. Schwarzenböck
1   Klinik für Nuklearmedizin, Universität, Rostock, Rostock
,
K. Herrmann
2   Klinik für Nuklearmedizin, Technische Universität, München
,
F. Gärtner
2   Klinik für Nuklearmedizin, Technische Universität, München
,
B. Kläsner
3   Institut für Radiologie und Nuklearmedizin, Klinikum Bogenhausen, München
,
M. Souvatzoglou
2   Klinik für Nuklearmedizin, Technische Universität, München
,
B. J. Krause
1   Klinik für Nuklearmedizin, Universität, Rostock, Rostock
› Author Affiliations
Further Information

Publication History

Publication Date:
03 August 2011 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Im Rahmen der Optimierung von Diagnostik und Therapie, u. a. der Bestrahlungstherapie, gewinnt in der Radioonkologie neben der [18F]FDG-Positronenemissiontomografie/Computertomografie (PET bzw. PET/CT) die PET/CT mit neuen Tracern zunehmend an Bedeutung.

Der Einsatz von [18F]Fluorothymidin ([18F]FLT) als Proliferationsmarker, [18F]Fluoromisonidazol ([18F]FMISO) und [18F]Fluoroazomycin-Arabinosid ([18F]FAZA) als Hypoxietracer, [18F]Fluoroethyltyrosin, ([18F]FET) und [11C]Methionin für die Hirntumorbildgebung, [68Ga]DOTATOC für die Somatostatinrezeptorbildgebung, [18F]FDOPA für die Dopaminsynthese und radioaktiv markierter Cholinderivate zur Phospholipidstoffwechsel-Bildgebung ist vielversprechend. Einige dieser neuen Tracer jenseits der FDG werden für radioonkologische Fragestellungen eingesetzt; so ist z. B. die Aminosäure-PET und -PET/CT hilfreich für eine optimierte Bestrahlungsplanung bei hirneigenen Tumoren, da FET und MET mit hoher Genauigkeit die Abgrenzung des Tumorgewebes vom Normalgewebe erlauben. Zukünftig wird die Etablierung und Validierung neuer Tracer für die Klinik, insbesondere auch für die Strahlentherapie, von Bedeutung sein. Tumorhypoxie bereitet im Rahmen der Bestrahlungsplanung therapeutische Schwierigkeiten. Die Hypoxiebildgebung könnte im Rahmen einer Intensitätsmodulierten Bestrahlungsplanung (IMRT) zu einer Therapieoptimierung beitragen.

Zudem haben Fortschritte in der Hybridbildgebungstechnologie der PET/MR hohes Potenzial in der bildgebenden Onkologie aufgrund der Synergie molekularer Information der PET mit dem höheren Weichteilkontrast, niedriger Strahlenbelastung und der Möglichkeit der morphologischen und funktionellen Bildgebung der MRT.

Abstract

PET and PET/CT with innovative tracers gain increasing importance in diagnosis and therapy management, and radiation treatment planning in radio-oncology besides the widely established FDG. The introduction of [18F]Fluorothymidine ([18F]FLT) as marker of proliferation, [18F]Fluoromisonidazole ([18F]FMISO) and [18F]Fluoroazomycin-Arabinoside ([18F]FAZA) as tracer of hypoxia, [18F]Fluoroethyltyrosine ([18F]FET) and [11C]Methionine for brain tumour imaging, [68Ga]DOTATOC for somatostatin receptor imaging, [18F]FDOPA for dopamine synthesis and radioactively labeled choline derivatives for imaging phospholipid metabolism have opened novel approaches to tumour imaging. Some of these tracers have already been implemented into radio-oncology: Amino acid PET and PET/CT have the potential to optimise radiation treatment planning of brain tumours through accurate delineation of tumour tissue from normal tissue, necrosis and edema. Hypoxia represents a major therapeutic problem in radiation therapy. Hypoxia imaging is very attractive as it may allow to increase the dose in hypoxic tumours potentially allowing for a better tumour control. Advances in hybrid imaging, i. e. the introduction of MR/PET, may also have an impact in radio-oncology through synergies related to the combination of molecular signals of PET and a high soft tissue contrast of MRI as well as functional MRI capabilities.

Schlüsselwörter

PET/CT - innovative Tracer - Cholin - Bestrahlungsplanung

Keywords

PET/CT - novel tracer - choline - radiation treatment planning
 

  • Literatur

  • 1 Barthel H, Perumal M, Latigo J et al. The uptake of 3′-deoxy-3′-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging 2005; 32: 257-263
    CrossrefPubMedGoogle Scholar
  • 2 Becherer A, Karanikas G, Szabo M et al. Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]Methionine. Eur J Nucl Med Mol Imaging 2003; 30: 1561-1567
    CrossrefPubMedGoogle Scholar
  • 3 Bott SR. Management of recurrent disease after radical prostatectomy. Prostate Cancer Prostatic Dis 2004; 7: 211-216
    CrossrefPubMedGoogle Scholar
  • 4 Briganti A, Chun FK, Salonia A et al. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol 2006; 50: 1006-1013
    CrossrefPubMedGoogle Scholar
  • 5 Buck AK, Herrmann K, Shen C et al. Molecular imaging of proliferation in vivo: positron emission tomography with [18F]Fluorothymidine. Methods 2009; 48: 205-215
    CrossrefPubMedGoogle Scholar
  • 6 Buck AK, Hetzel M, Schirrmeister H et al. Clinical relevance of imaging proliferative activity in lung nodules. Eur J Nucl Med Mol Imaging 2005; 32: 525-533
    CrossrefPubMedGoogle Scholar
  • 7 Chen W, Silverman DH, Delaloye S et al. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med 2006; 47: 904-911
    PubMedGoogle Scholar
  • 8 Chism DB, Hanlon AL, Horwitz EM et al. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys 2004; 59: 380-385
    CrossrefPubMedGoogle Scholar
  • 9 Ciernik IF, Brown DW, Schmid D et al. 3D-segmentation of the 18F-choline PET signal for target volume definition in radiation therapy of the prostate. Technol Cancer Res Treat 2007; 6: 23-30
    PubMedGoogle Scholar
  • 10 Fletcher JW, Djulbegovic B, Soares HP et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 2008; 49: 480-508
    CrossrefPubMedGoogle Scholar
  • 11 Francis DL, Visvikis D, Costa DC et al. Potential impact of [18F]3′-deoxy-3′-fluorothymidine versus [18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging 2003; 30: 988-994
    CrossrefPubMedGoogle Scholar
  • 12 Freedland SJ, Presti Jr. JC, Amling CL et al. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology 2003; 61: 736-741
    CrossrefPubMedGoogle Scholar
  • 13 Grosu AL, Weber WA, Franz M et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 2005; 63: 511-519
    CrossrefPubMedGoogle Scholar
  • 14 Heiss P, Mayer S, Herz M et al. Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo. J Nucl Med 1999; 40: 1367-1373
    PubMedGoogle Scholar
  • 15 Herrmann K, Eckel F, Schmidt S et al. In vivo characterization of proliferation for discriminating cancer from pancreatic pseudotumors. J Nucl Med 2008; 49: 1437-1444
    CrossrefPubMedGoogle Scholar
  • 16 Herrmann K, Ott K, Buck AK et al. Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis. J Nucl Med 2007; 48: 1945-1950
    CrossrefPubMedGoogle Scholar
  • 17 Herrmann K, Wieder HA, Buck AK et al. Early response assessment using 3′-deoxy-3′-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin′s lymphoma. Clin Cancer Res 2007; 13: 3552-3558
    CrossrefPubMedGoogle Scholar
  • 18 Hoegerle S, Altehoefer C, Ghanem N et al. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 2001; 28: 64-71
    CrossrefPubMedGoogle Scholar
  • 19 Kane CJ, Amling CL, Johnstone PA et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 2003; 61: 607-611
    CrossrefPubMedGoogle Scholar
  • 20 Kenny LM, Vigushin DM, Al-Nahhas A et al. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]Fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res 2005; 65: 10104-10112
    CrossrefPubMedGoogle Scholar
  • 21 Krause BJ, Beck R, Souvatzoglou M et al. PET and PET/CT studies of tumor tissue oxygenation. Q J Nucl Med Mol Imaging 2006; 50: 28-43
    PubMedGoogle Scholar
  • 22 Krause BJ, Souvatzoglou M, Herrmann K et al. [11C]Choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft model. Eur J Nucl Med Mol Imaging 2010; 37: 1861-1868
    CrossrefPubMedGoogle Scholar
  • 23 Krause BJ, Souvatzoglou M, Treiber U. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates. Urol Oncol 2011;
    PubMedGoogle Scholar
  • 24 Krause BJ, Souvatzoglou M, Tuncel M et al. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008; 35: 18-23
    CrossrefPubMedGoogle Scholar
  • 25 Lee NY, Mechalakos JG, Nehmeh S et al. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys 2008; 70: 2-13
    CrossrefPubMedGoogle Scholar
  • 26 Lin Z, Mechalakos J, Nehmeh S et al. The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography. Int J Radiat Oncol Biol Phys 2008; 70: 1219-1228
    CrossrefPubMedGoogle Scholar
  • 27 Nelson SJ. Imaging of brain tumors after therapy. Neuroimaging Clin N Am 1999; 9: 801-819
    PubMedGoogle Scholar
  • 28 Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005; 64: 479-489
    Google Scholar
  • 29 Ott K, Herrmann K, Schuster T et al. Molecular Imaging of Proliferation and Glucose Utilization: Utility for Monitoring Response and Prognosis after Neoadjuvant Therapy in Locally Advanced Gastric Cancer. Ann Surg Oncol. 2011
    PubMedGoogle Scholar
  • 30 Pasquier D, Ballereau C. Adjuvant and salvage radiotherapy after prostatectomy for prostate cancer: a literature review. Int J Radiat Oncol Biol Phys 2008; 72: 972-979
    CrossrefPubMedGoogle Scholar
  • 31 Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]Fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 2005; 128: 678-687
    CrossrefPubMedGoogle Scholar
  • 32 Popperl G, Goldbrunner R, Gildehaus FJ et al. O-(2-[18F]Fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging 2005; 32: 1018-1025
    CrossrefPubMedGoogle Scholar
  • 33 Popperl G, Gotz C, Rachinger W et al. Value of O-(2-[18F]Fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 2004; 31: 1464-1470
    CrossrefPubMedGoogle Scholar
  • 34 Popperl G, Gotz C, Rachinger W et al. Serial O-(2-[(18)F]Fluoroethyl)-L: -tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. Eur J Nucl Med Mol Imaging 2006; 33: 792-800
    CrossrefPubMedGoogle Scholar
  • 35 Popperl G, Kreth FW, Herms J et al. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?. J Nucl Med 2006; 47: 393-403
    PubMedGoogle Scholar
  • 36 Rachinger W, Goetz C, Popperl G et al. Positron emission tomography with O-(2-[18F]Fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery 2005; 57: 505-511 discussion 505–511
    CrossrefPubMedGoogle Scholar
  • 37 Rasey JS, Grierson JR, Wiens LW et al. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002; 43: 1210-1217
    PubMedGoogle Scholar
  • 38 Shields AF, Grierson JR, Dohmen BM et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998; 4: 1334-1336
    CrossrefPubMedGoogle Scholar
  • 39 Smith RA, Cokkinides V, Eyre HJ. Cancer screening in the United States, 2007: a review of current guidelines, practices, and prospects. CA Cancer J Clin 2007; 57: 90-104
    CrossrefPubMedGoogle Scholar
  • 40 Souvatzoglou MKB, Pürschel A, Thamm R et al. Influence of 11C-choline PET/CT on the treatment planning fpr savage radiation therapy in patients with biochemical recurrence of prostate cancer. Radiotherapy and Oncology in press 2011;
    PubMedGoogle Scholar
  • 41 Souvatzoglou M, Weirich G, Schwarzenboeck S et al. The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration. Clin Cancer Res 2011;
    PubMedGoogle Scholar
  • 42 Stephenson AJ, Scardino PT, Kattan MW et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007; 25: 2035-2041
    CrossrefPubMedGoogle Scholar
  • 43 Tuncel M, Souvatzoglou M, Herrmann K et al. [(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer. Nucl Med Biol 2008; 35: 689-695
    CrossrefPubMedGoogle Scholar
  • 44 Wagner M, Seitz U, Buck A et al. 3′-[18F]fluoro-3′-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease. Cancer Res 2003; 63: 2681-2687
    PubMedGoogle Scholar
  • 45 Weber WA, Wester HJ, Grosu AL et al. O-(2-[18F]Fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med 2000; 27: 542-549
    CrossrefPubMedGoogle Scholar
  • 46 Weckesser M, Langen KJ, Rickert CH et al. O-(2-[18F]Fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging 2005; 32: 422-429
    CrossrefPubMedGoogle Scholar
  • 47 Zander T, Scheffler M, Nogova L et al. Early Prediction of Nonprogression in Advanced Non-Small-Cell Lung Cancer Treated With Erlotinib By Using [18F]Fluorodeoxyglucose and [18F]Fluorothymidine Positron Emission Tomography. J Clin Oncolo 2011; 29: 1701-1708
    PubMedGoogle Scholar